. "Nucleophosmin (NPM1) mutations in exon 12 are the most common genetic alternation in cytogenetically normal AML (CN-AML). In this study, we have evaluated a novel, DNAbased real-time quantitative polymerase chain reaction (RQ-PCR) for the detection of three of the most commonly occurring mutations (A,B,D) and for six rare patient-specific mutation types, which represent 28% of all of the NPM1 mutations in our group of 25 CN-AML patients. Furthermore, the prognostic relevance of NPM1- based monitoring of minimal residual disease (MRD) in peripheral blood (PB), bone marrow (BM), and in specific cell subsets (CD341, CD342, CD34dim) of BM were evaluated. In 80% of the evaluable patients, a molecular relapse preceded a hematological relapse. Moreover, in this subset of patients, the molecular relapse occurred at a median of 97 days before the hematological relapse. Our analysis showed a strong correlation between BM and PB as well as a high copy number of mutated NPM1 in CD341 BM cells." . . "0361-8609" . "8"^^ . "Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations" . "Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations"@en . . "8"^^ . "RIV/65269705:_____/10:#0001006" . "Dvo\u0159\u00E1kov\u00E1, Dana" . "V, Z(MSM0021622430)" . . "Je\u017E\u00ED\u0161kov\u00E1, Ivana" . . . "Mayer, Ji\u0159\u00ED" . . "RIV/65269705:_____/10:#0001006!RIV11-MZ0-65269705" . "272484" . "R\u00E1\u010Dil, Zden\u011Bk" . . "Pal\u00E1sek, Ivo" . "12" . . "[59EFB514215D]" . "Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations" . . "4"^^ . "85" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . . . "Protiv\u00E1nkov\u00E1, Mark\u00E9ta" . . . "000285165300004" . . "minimal residual disease"@en . . . "Lengerov\u00E1, Martina" . "R\u00E1zga, Filip" . "American Journal of Hematology" . "Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations"@en . . . "Nucleophosmin (NPM1) mutations in exon 12 are the most common genetic alternation in cytogenetically normal AML (CN-AML). In this study, we have evaluated a novel, DNAbased real-time quantitative polymerase chain reaction (RQ-PCR) for the detection of three of the most commonly occurring mutations (A,B,D) and for six rare patient-specific mutation types, which represent 28% of all of the NPM1 mutations in our group of 25 CN-AML patients. Furthermore, the prognostic relevance of NPM1- based monitoring of minimal residual disease (MRD) in peripheral blood (PB), bone marrow (BM), and in specific cell subsets (CD341, CD342, CD34dim) of BM were evaluated. In 80% of the evaluable patients, a molecular relapse preceded a hematological relapse. Moreover, in this subset of patients, the molecular relapse occurred at a median of 97 days before the hematological relapse. Our analysis showed a strong correlation between BM and PB as well as a high copy number of mutated NPM1 in CD341 BM cells."@en . .